Comparison · NCT01227928-sae
Pazopanib 800 Milligrams vs Placebo: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Pazopanib 800 Milligrams vs Placebo: serious adverse events. Trial comparisons, record NCT01227928-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01227928-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0972 | 0.0479 | 0.187 | wilson | |
| Risk in group 2 | 0.0556 | 0.0218 | 0.134 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0417 | -0.0513 | 0.138 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.75 | 0.535 | 5.72 | log | |
| Odds ratio, group 1 over group 2 | 1.83 | 0.512 | 6.55 | log | |
| Number needed to harm, for one more participant with a serious adverse event on Pazopanib 800 Milligrams than on Placebo | 24 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Pazopanib 800 Milligrams | Participants received pazopanib 800 milligrams administered orally once daily for up to 24 months. | 7 | 72 | EG001 |
| Group 2 | Placebo | Participants received matching placebo administered orally once daily for up to 24 months. | 4 | 72 | EG000 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
Source ClinicalTrials.gov
Trial
- Title
- Efficacy and Safety of Pazopanib Monotherapy After First-line Chemotherapy in Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Asian Women
- NCT number
- NCT01227928
- Phases
- PHASE2
- Conditions
- Neoplasms, Ovarian
- Interventions
- Pazopanib, Placebo comparator
- Lead sponsor
- GlaxoSmithKline
- Results first posted
- 2013-06-04
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01227928?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01227928-sae